Status:

ACTIVE_NOT_RECRUITING

Prepectoral and Subpectoral Implant-based Breast Reconstruction

Lead Sponsor:

Fudan University

Conditions:

Breast Carcinoma

Breast Reconstruction

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

Breast cancer is one of the main malignant tumors threatening women's lives. In recent years, the increasing demand for reconstruction of breast cancer patients in China has made the proportion of bre...

Eligibility Criteria

Inclusion

  • More than 18 years old
  • Female
  • Preoperative pathology confirming invasive breast carcinoma or ductal carcinoma in situ
  • Clinical T1 and T2 (Maximum tumor diameter ≤5 cm)
  • Clinical ALN negative (Clinical physical examination and ultrasound indicate axillary lymph node negative; Suspected abnormality of axillary lymph node, and fine needle aspiration negative)
  • No clinical or imaging evidence of distant metastasis
  • Patients to receive skin sparing mastectomy or nipple sparing mastectomy
  • BMI \< 35
  • Patients with no or mild mastoptosis
  • Prosthesis to be implanted \<500 ml
  • Be able and willing to sign the Informed Consent Form (ICF)

Exclusion

  • Patients with the breast of moderate-severe mastoptosis, or requiring the use of Wise-pattern or other breast lift methods for subcutaneous mammary gland resection
  • BMI\>=35
  • Patients who have received symmetrical breast surgery on the unaffected side immediately or later
  • Patients with locally advanced breast cancer to receive neoadjuvant therapy
  • Patients currently participating in other clinical trials, which may have impact on the participation in this trial
  • Neoadjuvant therapy has been completed, and there is clear indication of adjuvant radiotherapy after the operation
  • Previous history of breast cancer (patients with ipsilateral recurrence after breast sparing surgery)
  • Pregnancy breast-feeding women
  • History of smoking
  • Previous history of diabetes

Key Trial Info

Start Date :

May 12 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT04688697

Start Date

May 12 2021

End Date

December 31 2025

Last Update

April 2 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fudan University Shanghai Cancer Center

Shanghai, China